收费全文 | 1378018篇 |
免费 | 96471篇 |
国内免费 | 3108篇 |
耳鼻咽喉 | 20166篇 |
儿科学 | 41176篇 |
妇产科学 | 39385篇 |
基础医学 | 194699篇 |
口腔科学 | 40829篇 |
临床医学 | 116270篇 |
内科学 | 270223篇 |
皮肤病学 | 31168篇 |
神经病学 | 110762篇 |
特种医学 | 55317篇 |
外国民族医学 | 435篇 |
外科学 | 214220篇 |
综合类 | 31243篇 |
现状与发展 | 6篇 |
一般理论 | 484篇 |
预防医学 | 94475篇 |
眼科学 | 32187篇 |
药学 | 103220篇 |
4篇 | |
中国医学 | 3023篇 |
肿瘤学 | 78305篇 |
2018年 | 12570篇 |
2016年 | 11425篇 |
2015年 | 12753篇 |
2014年 | 17851篇 |
2013年 | 26959篇 |
2012年 | 35354篇 |
2011年 | 37367篇 |
2010年 | 22295篇 |
2009年 | 21723篇 |
2008年 | 36049篇 |
2007年 | 39214篇 |
2006年 | 39583篇 |
2005年 | 38412篇 |
2004年 | 37338篇 |
2003年 | 36182篇 |
2002年 | 35788篇 |
2001年 | 64016篇 |
2000年 | 65615篇 |
1999年 | 55817篇 |
1998年 | 15219篇 |
1997年 | 13942篇 |
1996年 | 13364篇 |
1995年 | 12611篇 |
1994年 | 11819篇 |
1992年 | 43022篇 |
1991年 | 41517篇 |
1990年 | 40762篇 |
1989年 | 39739篇 |
1988年 | 37151篇 |
1987年 | 36566篇 |
1986年 | 35063篇 |
1985年 | 33290篇 |
1984年 | 25033篇 |
1983年 | 21250篇 |
1982年 | 12900篇 |
1981年 | 11790篇 |
1979年 | 24047篇 |
1978年 | 17230篇 |
1977年 | 14984篇 |
1976年 | 13525篇 |
1975年 | 15375篇 |
1974年 | 18190篇 |
1973年 | 17664篇 |
1972年 | 16905篇 |
1971年 | 15785篇 |
1970年 | 14979篇 |
1969年 | 14411篇 |
1968年 | 13506篇 |
1967年 | 12080篇 |
1966年 | 11331篇 |
Method: Socio-demographics, early-life adversity (ELA), individual quality of life (iQoL), and mental and physical health of 270 individuals (Mage = 66.82 years, 71.5% female) were assessed. Polynomial regressions and mediation analyses were conducted.
Results: Significant inverse U-shaped associations were found between ELA and iQoL (β = ?.59, p = .005) and between ELA and mental health (β = ?.64, p = .002), but not between ELA and physical health. Furthermore, mental health significantly mediated the relationship between ELA and iQoL (b = ?.84, BCa CI [?1.66, ?.27]).
Conclusion: Highest level of individual quality of life (i.e. successful aging) was related to a moderate amount of ELA. Additionally, mental health significantly mediated this relationship. These findings suggest that some amount of ELA could be beneficial for successful aging. Resource-focused interventions are needed to improve health and promote successful aging for an underdetected, at-risk subgroup with low early-life adversity. 相似文献
Introduction
Physician communication impacts patient outcomes. However, communication skills, especially around difficult conversations, remain suboptimal, and there is no clear way to determine the validity of entrustment decisions. The aims of this study were to 1) describe the development of a simulation-based mastery learning (SBML) curriculum for breaking bad news (BBN) conversation skills and 2) set a defensible minimum passing standard (MPS) to ensure uniform skill acquisition among learners.Innovation
An SBML BBN curriculum was developed for fourth-year medical students. An assessment tool was created to evaluate the acquisition of skills involved in a BBN conversation. Pilot testing was completed to confirm improvement in skill acquisition and set the MPS.Outcomes
A BBN assessment tool containing a 15-item checklist and six scaled items was developed. Students' checklist performance improved significantly at post-test compared to baseline (mean 65.33%, SD = 12.09% vs mean 88.67%, SD = 9.45%, P < 0.001). Students were also significantly more likely to have at least a score of 4 (on a five-point scale) for the six scaled questions at post-test. The MPS was set at 80%, requiring a score of 12 items on the checklist and at least 4 of 5 for each scaled item. Using the MPS, 30% of students would require additional training after post-testing.Comments
We developed a SBML curriculum with a comprehensive assessment of BBN skills and a defensible competency standard. Future efforts will expand the mastery model to larger cohorts and assess the impact of rigorous education on patient care outcomes. 相似文献Areas covered: This article covers the pharmacokinetics and pharmacodynamics of vilazodone and provides an evaluation of the clinical usefulness of vilazodone for the treatment of MDD and anxiety disorders. A literature search was performed using PubMed/MEDLINE, Web of Science and the Cochrane Library.
Expert opinion: Studies have shown that vilazodone is significantly superior to placebo. However, vilazodone cannot as yet be recommended as a first-line treatment option for MDD as it is unclear whether the drug’s dual mechanism of action provides greater efficacy than prevailing treatment options. Moreover, more phase IV studies are needed to establish its efficacy and long-term safety in larger and more diverse populations. Although vilazodone may have an additional advantage for the treatment of anxiety symptoms in MDD, here also additional studies are required to confirm its efficacy over and above SSRI alternatives and other antidepressant treatments. Therefore, presently, vilazodone should be considered as a second- or third-line treatment option for MDD and GAD. 相似文献